Lecanemab, approved by the Food and Drug Administration last year, and donanemab, out earlier this month, are both antibody treatments built around the idea that reducing the presence of key amyloid plaques in the brain will help slow dementia progression
Individual research outcomes may vary, and Legendary Peptides makes no representations or guarantees regarding specific findings, changes in body composition, or any other measurable results
This does the whole vial divide into a sensible number of draws? check is the cheapest and most powerful guard against order-of-magnitude mistakes
WADA prohibits BPC-157 at all times, in and out of competition
STEP 8 (N = 338, randomized 1:1:1) was the only trial that included an active comparator, liraglutide, as well as corresponding placebo controls for each of the active treatment groups